Advertisement

L’Endocrinologo

, Volume 7, Issue 4, pp 187–193 | Cite as

Corretto uso dei marcatori del rimodellamento osseo

  • Vincenzo De Paola
  • Giuseppe Martini
  • Daniela Merlotti
  • Stefania Salvadori
  • Fabrizio Valleggi
  • Luigi Gennari
  • Ranuccio Nuti
Article
  • 36 Downloads

Riassunto

Imarker del turnover osseo rappresentano un mezzo di valutazione dinamica dello scheletro che aggiungono informazioni alla valutazione statica fornita dalla densitometria ossea. Numerosi studi hanno dimostrato che esiste un’associazione fra i marker ed il rischio di frattura, ma ancora è difficile trasferire questi dati nella gestione del singolo paziente. Probabilmente il maggior potenziale dei marker risiede nel loro utilizzo per il monitoraggio della terapia dell’osteoporosi, soprattutto quando vengono utilizzati farmaci antiriassorbitori, sia per la valutazione della compliance dei pazienti che per la valutazione dell’effetto terapeutico.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Garnero P, Delmas PD. Biochemical markers of bone turnover: clinical usefulness in osteoporosis. Ann Biol Clin (Paris) 57: 137, 1999.Google Scholar
  2. 2.
    Sambrook P, Cooper C. Osteoporosis. Lancet 367: 2010, 2006.PubMedCrossRefGoogle Scholar
  3. 3.
    Delmas PD. How should the risk of fracture in postmenopausal women be assessed? Osteoporos Int 9 (Suppl 2): S33, 1999.PubMedCrossRefGoogle Scholar
  4. 4.
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11 (Suppl 6): S2, 2000.PubMedCrossRefGoogle Scholar
  5. 5.
    Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 11 (Suppl 6): S18, 2000.PubMedCrossRefGoogle Scholar
  6. 6.
    Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom 2: 299, 1999.PubMedCrossRefGoogle Scholar
  7. 7.
    Hart SM, Eastell R. Biochemical markers of bone turnover. Curr Opin Nephrol Hypertens 8 (Suppl 4): 421, 1999.PubMedCrossRefGoogle Scholar
  8. 8.
    Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH. Clinical use of biochemical markers of bone remodelling: Current status and future directions. Osteoporos Int 11: 467, 2000.PubMedCrossRefGoogle Scholar
  9. 9.
    Swaminathan R. Biochemical markers of bone turnover. Clinica Chimica Acta 313: 95, 2001.CrossRefGoogle Scholar
  10. 10.
    Gonnelli S, Cepollaro C, Montagnani A, Monaci G, Campagna MS, Franci MB, Gennari C. Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases. Eur J Clin Invest 26: 391, 1996.PubMedCrossRefGoogle Scholar
  11. 11.
    Lindsay R. Clinical utility of biochemical markers. Osteoporos Int 9 (Suppl 2): 529, 1999.Google Scholar
  12. 12.
    Nishizawa Y, Toshitaka N, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 23: 97, 2004.CrossRefGoogle Scholar
  13. 13.
    Perrien DS, Achenbach SJ, Bledsoe SE, Walser B, Suva LJ, Khosla S, Gaddy D. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab 91: 1848, 2006.PubMedCrossRefGoogle Scholar
  14. 14.
    Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol 11: 312, 1999.PubMedCrossRefGoogle Scholar
  15. 15.
    Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 1359, 1999.PubMedGoogle Scholar
  16. 16.
    Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 (Suppl 6): S55, 2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (Suppl 8): 1526, 2000.PubMedCrossRefGoogle Scholar
  18. 18.
    Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11 (Suppl 6): S66, 2000.PubMedCrossRefGoogle Scholar
  19. 19.
    Roux C, Garnero P, Thomas T, Sebatier JP, Orcel P, Audran M; Comité Scientifique du GRIO. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 72: 26, 2005.PubMedCrossRefGoogle Scholar
  20. 20.
    Weisman SM, Matkovic V. Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk. Clin Ther 27 (Suppl 3): 299, 2005.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2006

Authors and Affiliations

  • Vincenzo De Paola
    • 1
  • Giuseppe Martini
    • 1
  • Daniela Merlotti
    • 1
  • Stefania Salvadori
    • 1
  • Fabrizio Valleggi
    • 1
  • Luigi Gennari
    • 1
  • Ranuccio Nuti
    • 1
  1. 1.Dipartimento di Medicina Interna, Scienze Endocrino-Metaboliche e BiochimicaUniversità di Siena, Policlinico “Le Scotte”SienaItalia

Personalised recommendations